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Photoactivated antiviral and antitumor compositions
Abstract
Disclosed herein are compounds, compositions, and methods to inactivate a virus and destroy tumor cells.
The methods involve the addition into the cell of a compound containing a photosensitizing chemical and an
energy donating chemical, optionally linked by a chemical tether. Also introduced into the cell are means to
chemically activate the energy donating chemical which photoactivates the photosensitizing chemical which
then destroys the tumor or virus. The photosensitizing chemical is preferably hypericin, porphyrin, or an
analog and the energy donating chemical is preferably luciferin or an analog. Methods for synthesizing the
chemicals are also disclosed. Further, the energy donating chemical is activated by an activating chemical. The
expression of the activating chemical is regulated so as to target the virus-infected or tumor cells. Regulating
the activating chemical is accomplished by a number of methods including construction of an expression
plasmid containing a gene encoding the activating chemical under control of a promoter which is
transactivated by replication of the virus or transactivated by elevated levels of proteins expressed in tumor
cells.
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sensitizing chemical which then destroys the tumor or virus. 
The photosensitizing chemical is preferably hypericin. 
porphyrin. or an analog and the energy donating chemical is 
preferably luciferin or an analog. Methods for synthesizing 
the chemicals are also disclosed. Further. the energy donat 
ing chemical is activated by an activating chemical. The 
expression of the activating chemical is regulated so as to 
target the virus-infected or tumor cells. Regulating the 
activating chemical is accomplished by a number of meth 
ods including construction of an expression plasmid con 
taining a gene encoding the activating chemical under 
control of a promoter which is transactivated by replication 
of the virus or transactivated by elevated levels of proteins 
expressed in tumor cells. 
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PHOTOACTIVATED ANTIVIRAL AND 
ANTITUMOR COMPOSITIONS 
The following is a continuation-in-part of US. patent 
application Ser. No. 07/995.877 ?led Dec. 23. 1992. now 
abandoned. 
FIELD OF THE INVENTION 
This invention relates to compositions containing photo 
dynamic molecules and means for activating the antiviral 
and antitumor properties of such molecules within viral 
infected and tumor cells without an external light source. 
BACKGROUND OF THE INVENTION 
In recent years. photodynamic therapy (PDT) has 
emerged as a promising tool in both antiviral and cancer 
chemotherapy. In the presence of light of the appropriate 
wavelengths. the photoactive molecule absorbs the light and 
inactivates the virus or destroys the tumor cell. Photoactive 
molecules which are currently employed include a mixture 
of compounds called hematoporphyrin derivatives (HpD). 
the purpun'ns and the phthalocyanines. Amajor drawback is 
that PDT cannot be extended to treatment in regions of the 
body where light does not penetrate. 
Moan et al.. "Yearly Review: Porphyrin Photosensitiza 
tion and Phototherapy." Photochemistry and Photobiology: 
Vol. 43. No. 6. pp. 681-690 (1986). which is incorporated 
herein in its entirety by reference. discloses the tumor 
localizing property of porphyrins and their use in PDT. The 
method of treatment involves direct injection of the photo 
sensitizer. The photosensitizer molecules are affected by a 
light source located outside the body. Moan et al. speci?cally 
mention that because penetration of light is limited. PDT can 
never be used to eliminate large tumors. 
Meruelo et al.. "Therapeutic Agents With Dramatic Anti 
retroviral Activity and Little Toxicity at Effective Doses: 
Aromatic Polycyclic Diones Hypericin and 
Pseudohypericin.” Proc. Natl. Acaa'. Sci, Vol. 85. pp. 
5230-5234 (1988). which is incorporated herein in its 
entirety by reference. have demonstrated that hypericin 
inhibits the replication of Friend leukemia virus and radia 
tion leukemia virus. both in vitro and in vivo. Meruelo et al. 
stated that when hypericin was administered to mice at doses 
su?icient to prevent retroviral-induced disease. the mice 
appeared to be devoid of undesirable side effects. Meruelo 
et al. have also reported that hypericin can reduce the spread 
of HIV. Meruelo et al. speculate that hypericin may act by 
direct inactivation of the virions. 
Chanh et al.. “Photodynamic Inactivation of Simian 
Immunode?ciency Virus." J. of Wmlogical Methods, Vol. 
26. pp. 125-132 (1989). which is incorporated herein in its 
entirety by reference. disclose photodynamic inactivation of 
simian irmnunode?ciency virus (SIV). A dihematoporphyrin 
ether (DHE) was used to inactivate. in vitro. the infectivity 
of SIV. DHE was activated through the use of a laser beam. 
The experiment was conducted by incubating SIV sus 
pended in a culture medium with DHE in the dark. followed 
by irradiation. The authors postulated that this treatment will 
reduce the risk of infection by enveloped viruses during 
transfusions. 
Lavie et al.. “Studies of Mechanisms of Action of the 
Antiretroviral Agents Hypericin and Pseudohypericin.” 
Proc. Natl. Acad. Sci, Vol. 86. pp. 5963-5967 (1989). which 
is incorporated herein in its entirety by reference. disclose 
that hypericin and pseudohypericin possess anti-retroviral 
activity. Speci?cally. the hypericin and pseudohypericin 
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suppress the spread of murine retrovirus in vitro and in vivo. 
Treatment by hypericin and pseudohypericin resulted in 
complete inactivation of reverse transcriptase of both murine 
and human viruses when the compounds were administered 
by injection. 
Hudson et al.. “Antiviral Activities of Hypericin.” Anti 
viral Research, Vol. 15. pp. 101-112 (1991). which is 
incorporated herein in its entirety by reference. disclose that 
hypericin inactivates murine cytomegalovirus (MCMV) 
Sindbis Virus. and HIV-1. 
US. Pat. Nos. 4.898.891. 5.049.589 and 5.047.435 to 
Lavie et al.. all of which are incorporated herein by 
reference. disclose the antiviral effects of hypericin and 
pseudohypericin and antiviral pharmaceutical composition 
containing hypericin as an active ingredient. 
Finally. Matthews et al.. “Photodynamic Therapy of Viral 
Contaminants with Potential for Blood Banking 
Applications." Transfusion, Vol. 28. No. 1. pp. 81-83 
(1988). which is incorporated herein in its entirety by 
reference. disclose PDT for eradicating viral contaminants. 
The method employs a hematoporphyrin derivative used as 
the photosensitizer to inactivate an enveloped virus. The 
method involves extracorporeal plasmaphoresis. i.e.. the 
blood is taken out of the body prior to being treated with 
hematoporphyrin and light. The method uses visible light. 
There is a need to connect an energy source to photoactive 
molecules so that PDT can be expanded to all regions of the 
body. There is also a need to provide a method for targeting 
PDT to viral infected cells or to tumor cells. 
Thus. activation of the energy source must be regulated 
such that activation preferentially occurs in the virus 
infected cells or tumor cells. The present invention over 
comes the problems in the prior art by employing an energy 
source which (1) emits energy in a broad band of wave 
lengths in the range in which the photoactive molecule 
absorbs and (2) is chemically activated by another chemical. 
which is regulated to express in the virus-infected or tumor 
cell. Thus. photoactivation of the photosensitizer is targeted 
to the virus-infected or tumor cells. The inventors have also 
developed chemical tethers to connect the energy source and 
the photoactive molecule. The use of such a tethered com 
pound allows for the in vivo introduction of an internal 
chemically-activated light source having broad applications 
in antiviral and tumor thm'apy. 
SUMMARY OF THE INVENTION 
It is an object of the present invention to provide antiviral 
compositions. 
It is a further object of the invention to provide tethered 
compounds for use in the antiviral compositions. 
Another object of the invention is to provide antitumor 
compositions. 
Another object of the invention is to provide tethered 
compounds for use in the antitumor compositions. 
Another object of the invention is to provide hypericin 
analogs for use as intermediates in the preparation of the 
tethered compounds. 
Another object of the invention is to provide luciferin and 
its analogs for use as intermediates in the preparation of the 
tethered compounds. 
Yet another object of the invention is to provide methods 
for synthesizing precursors of the luciferin analogs. 
Yet another object of the invention is to provide methods 
for synthesizing the tethered compounds. 
A still further object of the invention is to provide means 
for activating the tethered compounds. 
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A still further object of the invention is to provide 
expression plasmids for activating the tethered compounds. 
A still further object of the invention is to provide a 
liposome containing an expression plasmid. 
A still further object of the invention is to provide a 
transfected cell containing an expression plasmid. 
A still further object of the invention is to provide an 
eukaryotic cell containing a stably integrated copy of an 
expression plasmid. 
A still further object of the invention is to provide a viral 
vector produced from the eukaryotic cell. 
Additional objects and advantages of the invention will be 
set forth in part in the description which follows. and in part 
will be obvious from the description. or may be learned by 
the practice of the invention. The objects and advantages of 
the invention will be attained by means of the instrumen 
talities and combinations particularly pointed out in the 
appended claims. 
To achieve the objects in accordance with the purpose of 
the invention as embodied and broadly described herein. the 
present invention provides a composition for inactivating a 
virus or destroying a tumor cell. The composition preferably 
contains three components. The ?rst component is a chemi 
cal capable of photosensitization. hereinafter termed “a 
photosensitizing chemical.” The second component is an 
energy donating chemical. The third component contains 
means for activating the transfer of energy or the emission 
of light ?om the energy donating chemical. The present 
invention preferably employs luciferin. a natural light 
source. or its analogs as the energy donating chemical. The 
photosensitizing chemical is preferably hypericin. a 
porphyrin. or one of their analogs. 
In a preferred antiviral composition. as well as in a 
preferred antitumor composition. the hypericin. porphyrin. 
or analog is connected to the luciferin or analog. by way of 
a chemical tether or chemical linker. Thus. in a preferred 
embodiment of the invention. the ?rst and second compo 
nents of the antiviral or antitumor composition. i.e.. the 
photosensitizing chemical and the energy emitting chemical. 
are connected by a chemical tether and form a tethered 
compound. As used herein. “chemical tether" or "chemical 
linker" is a chemical connector of two compounds. 
The hypericin-luciferin tethered compound is preferably 
prepared through a condensation reaction of an activated 
hypericin with a luciferin analog. The luciferin analogs are 
synthesized from lmown compounds. 
The compositions of the present invention also preferably 
contain a third component that contains chemical means for 
activating the transfer of energy or emission of light from the 
energy donating chemical. The chemical means of the 
present invention is preferably an activating chemical 
encoded by a gene under control of regulatory genetic 
elements. The DNA controlling the activating chemical 
operably contains regulatory motifs recognized by host cell 
transcription factors in addition to motifs recognized by viral 
regulatory proteins. As used herein. “regulatory element” 
(“regulatory nucleic acid sequence”) is a region (sequence) 
that determines when. if. and at what level the DNA encod 
ing the activating chemical is expressed. Such regulatory 
elements include promoters. enhancers. and transcription 
and translation initiation and termination sequences. As used 
herein. “nucleic acid sequence” refers generally to a poly 
nucleotide molecule. more speci?cally to a linear series of 
nucleotides connected one to the other by phosphodiester 
bonds between the 3' and 5' carbons of the two adjacent 
pentoses. 
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Luciferin. a preferred energy donating molecule of the 
present invention. transfers energy or emits light when it 
reacts with the enzyme luciferase. ATP. and molecular 
oxygen. i.e.. when the luciferase activates luciferin. 
Therefore. luciferase is an activating chemical when 
luciferin is the energy donating chemical. Thus. another 
preferred embodiment of the invention is regulating the 
expression of luciferase such that luciferase is preferentially 
or only expressed in virus-infected or tumor cells. 
Regulating the activating chemical of an antiviral com 
position is preferably accomplished by ?rst constructing an 
expression plasmid containing a gene encoding the activat 
ing chemical under control of a promoter. The DNA encod 
ing the activating chemical is inserted into a vector. such as 
an expression plasmid. in proper orientation and correct 
reading frame for expression. Preferably. the antiviral com 
position is used to inactivate an enveloped virus but may be 
used for inactivating any viruses. More preferably. the 
antiviral composition is used to inactivate DNA enveloped 
viruses such as Herpes Simplex Virus and RNA enveloped 
viruses such as lentiviruses HIV and EIAV. The expression 
plasmid preferably contains a luciferase gene under control 
of an enveloped virus promoter. e.g.. the retrovirus long 
terminal repeat (LTR). The promoter is selected such that 
replication of the virus will transactivate the promoter 
resulting in increased expression of luciferase leading to 
activation of luciferin and photoactivation of hypericin. 
Thus. photoactivation is localized to the virus-infected cells. 
thereby targeting the antiviral activity of the photosensitiz 
ing chemical. 
The expression plasmid may be introduced into a cell by 
a variety of known methods including incorporation into a 
liposome. Other known methods that may be employed 
include. but are not limited to. the use of naked DNA 
transfer. microinjection. or calcium phosphate precipitation. 
A viral vector may also be constructed and introduced into 
a cell by viral mediated gene therapy or other known gene 
therapy techniques. Such a viral vector is preferably con 
structed by stably integrating a copy of the expression 
plasmid into a cell line. The viral vector is then produced 
from the cell line. 
For use in an antitumor composition. the regulation of the 
activating chemical is also preferably accomplished by 
constructing an expression plasmid. The expression plasmid 
contains the gene encoding the activating chemical. e.g.. 
luciferase. in an embodiment when luciferin is the energy 
donating chemical. under control of a promoter. The pro 
moter is transactivated by elevated levels of proteins 
expressed in tumor cells. Transactivating the promoter 
increases expression of luciferase which activates luciferin 
and photoactivates the photosensitizing chemical. i.e.. 
hypericin. in one embodiment. Thus. photoactivation is 
localized to the tumor cell. thereby targeting the antitumor 
activity of the photosensitizing chemical. 
The expression plasmid used for regulating the activating 
chemical of the antitumor composition may be introduced 
into a cell by methods similar to those discussed for the 
antiviral composition. These methods include. but are not 
limited to. incorporation into a liposome. naked DNA 
transfer. microinjection. or calcium phosphate precipitation. 
A viral vector may also be constructed and introduced into 
a cell through known gene therapy techniques as discussed 
above. 
The tethered compounds of the present invention are 
generally synthesized through a condensation reaction of the 
energy donating chemical with the photosensitizing chemi 
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cal. In preferred embodiments of the present invention. the 
tethered compounds are synthesized by condensing a 
porphyrin. hypericin or their analogs with luciferin or its 
analogs. 
Although luciferin is the presently preferred energy 
donating chemical. and hence luciferase the preferred acti 
vating chemical. there are various other chemical systems 
that produce sut?cient energy or light to activate the pho 
tosensitizing chemical component of the compositions and 
methods of the invention. One particularly preferred energy 
donating chemical alternative to luciferin is dioxetane. 
Where dioxetane is the second component. i.e.. the energy 
donating chemical. the chemical means (third component) 
for activating the transfer of energy or the emission of light 
is a “trigger” moiety attached to the dioxetane molecule but 
readily cleaved therefrom. Thus the activating chemical 
means of the invention need not be an expression plasmid. 
Depending on the virus or neoplastic cell to be targeted. the 
trigger may be. for example. a polypeptide that is cleaved by 
a protease produced by the virus or neoplastic cell. In 
addition. as will be shown in the detailed description which 
follows, the dioxetane itself preferably comprises a tethered 
compound. in which case the stable dioxetane contains both 
the photosensitizing chemical and the trigger. When the 
trigger is cleaved by the virus or neoplastic cell enzyme 
product or other targeted reagent. the dioxetane becomes 
unstable and produces an excited singlet. i.e.. is activated. to 
activate the photosensitizing chemical moiety. which in turn 
inactivates the virus or kills the neoplastic cell. 
The antiviral composition of the present invention may be 
used in a method for inactivating a virus. In a preferred 
method. the ?rst and second components of the antiviral 
composition. preferably in the form of a tethered compound. 
are administered in pharrnaceutically etfective amount to the 
virus-infected cell. In addition. the third component of the 
antiviral composition. i.e.. the component containing the 
chemical means for activating the transfer of energy or the 
emission of light. is also administered to the virus-infected 
cell. as discussed above. where it then activates the energy 
donating chemical which activates the photosensitizing 
chemical which inactivates the virus. 
The antitumor composition of the present invention may 
be used in a method for treating tumors by destroying 
neoplastic cells. In a preferred method. the ?rst and second 
components of the antitumor composition. preferably in the 
form of a tethered compound. are administered in a phar 
maceutically e?ective amount to a neoplastic cell. In 
addition. the third component of the antitumor composition. 
i.e.. the component containing the chemical means for 
activating the transfer of energy or the emission of light. is 
also administered to the neoplastic cell. as discussed above. 
where it then activates the energy donating chemical which 
then activates the photosensitizing chemical which destroys 
the neoplastic cell. 
DESCRIPTION OF THE FIGURES 
FIG. 1 is a graphic representation of the comparison of the 
chemiluminescent emission spectrum of the luciferase 
catalyzed oxidation of luciferin and the absorption spectrum 
of hypericin in the red region of the visible spectrum. 
FIG. 2 is a graphic representation of the time course of the 
chemiluminescent emission from the luciferase-catalyzed 
oxidation of luciferin. The concentration of the reactants are 
as follows: [luciferase]=2.67><10_7M. [luciferin]=1.l8><l0' 
6M. [ATPl=5><lO"9M; the buffer is 25 mM glycylglycine. 15 
mM MgSO4. 4 mM EGTA. 15 mM K3PO4 at pH=7.75 and 
the reaction is carried out at 25° C. 
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FIG. 3A is a representation of an expression plasmid 
containing the luciferase gene under the control of the ELAV 
LTR. FIG. 3B is a representation of a retroviral vector 
containing the luciferase gene under the control of the HIV 
LTR. This vector may be used for killing HIV/HIV-infected 
cells. FIG. 3C shows the construct of a retroviral vector for 
cell-speci?c lo'lling of melanoma cells. 
FIG. 4 shows the antiviral activity of hypen'cin in the 
presence of luciferin and luciferase. 
FIG. 5 shows the expression of luciferase in ED cells in 
the presence of EIAV or E'I‘at. 
FIG. 6 shows 100-1000 fold reduction in virus production 
in infected cells treated with the expression plasmid of FIG. 
3A and a tethered hypericin-luciferin compound according 
to the invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Reference will now be made in detail to the presently 
preferred embodiments of the invention. which together 
with the following examples. serve to explain the principles 
of the invention. 
The invention relates to antiviral and antitumor compo 
sitions comprising a ?rst component containing a photosen 
sitizing chemical. a second component containing an energy 
donating chemical. and preferably a third component con 
taining means for regulating the emission of light or transfer 
of energy as well as to methods for synthesizing such 
components. The energy donating molecule should emit 
energy or light in a broad band of wavelengths in the range 
where the photoactive chemical absorbs. As used herein. a 
photosensitizing chemical is a chemical that is activated by 
light or energy transfer. 
A preferable natural energy source is luciferin and its 
analogs. The reaction of luciferin with the enzyme 
luciferase. ATP. and molecular oxygen produces an intense 
long-lived emission from a triplet state. phosphorescence. 
The light produced by luciferin and its analogs is in the 
520-680 nm region. Lucifen'n does not emit light or energy 
unless activated. Thus. regulating the expression of 
luciferase regulates the activation of luciferin. 
The reaction of luciferin and luciferase provides lumines 
cence reactions with the highest known quantum yields. 
However. various other energy donating chemicals provide 
signi?cant quantum yields and may be used for activating 
the photosensitizing chemical according to the present 
invention. Such energy donating means. in addition to 
luciferin. include. but are not limited to. dioxetanes. 
dioxetanones. dioxetanediones and various other chemi- and 
bioluminescent compounds known in the art. for example. 
phthalhydrazide and compounds having oxygen-oxygen 
single bonds. such as hydroperoxides. See. e.g.. Mayer and 
Neuenhofer. Angew. Chem. Int. Ed. Eng., 33. 1044-1072 
(1994). which is incorporated herein by reference in its 
entirety. Of these luciferin alternatives. 1.2-dioxetane is 
currently the most preferred. 
The photosensitizing chemical is preferably one selected 
from hypericin. other quinones. hematoporphyrin 
derivatives. phthalocyanins and porphyrins. A speci?c 
embodiment involves the use of hypericin as the photosen 
sitizing chemical. Hypericin absorbs light in the 540-660 
nm range. When hyper-icin is photoacn'vated. it produces 
singlet oxygen with a quantum yield of 0.74. 
The energy transfer e?iciency is optimized by connecting 
the energy donating chemical to a photosensitizing chemical 
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by way of a chemical tether. The chemical tether connects 
the two ring compounds. Thus. a preferred embodiment of 
the invention includes the ?rst and second components in the 
form of a tethered compound 
The tethering of the photosensitizing chemical and the 
energy donating chemical is directed to ?nding the most 
e?icient energy transfer between. the donor and the acceptor. 
The most ef?cient transfer depends on the relative separation 
and orientation of each of the two components. 
Speci?cally. a preferred embodiment is directed to the 
connection between hypericin and luciferin or its analogs. 
Hypericin is a preferred photosensitizing chemical because 
low dosage administration of hypericin avoids undesirable 
side e?iects. 
One embodiment of the invention is directed to the use of 
an activated hypericin analog. an anhyride or halide. for use 
as an intermediate in the preparation of the tethered com 
pound. The anhyride and halide have the following formula: 
OH O OH 
OH 
O 
O Q 
0 OH OH 
OH or 
OH 
The anhyride can be prepared in three steps from hyperi 
cin. Acetylation of hypericin followed by chromic acid 
oxidation generates the diacid. which when reacted with 
DCC completes the synthesis of the anhydride. The halide is 
made by acetylation followed by benzylic halogenation. 
Another embodiment of the invention is directed to using. 
as the photosensitizing chemical. porphyrins of the follow 
ing formula: 
25 
30 
35 
45 
C02 
wherein 21-26 are alkyl or alkenyl groups having l-l5 
carbon atoms. 
Luciferin and its analogs can be used to form tethered 
compounds with photoactive chemicals such as phorphyrins. 
hypericin. or other quinones. The tethered compounds must 
demonstrate overlap in the absorption spectra of the selected 
photoactive chemical with the emissions spectra of the 
energy donating chemical. 
When oxidized luciferin’s broad emission band is cen 
tered at 560 nm and overlaps the two strongly absorbing 
bands of hypericin in the red region of the visible spectrum 
at 555 and 600 um. See FIG. 1 for a comparison of the 
spectrum of the chemiluminescent emission of the 
luciferase-catalyzed oxidation of lueifen'n and the absorp 
tion spectrum of hypericin in the red region of the visible 
spectrum. This overlap allows for luciferin to be paired with 
hypericin. 
During the luciferase-catalyzed oxidation of luciferin. one 
photon of light is produced per molecule of substrate con 
sumed. FIG. 2 presents the time course of the chemilu 
minesecent reaction of luciferin. The tethering of luciferin or 
its analogs must not disrupt the recognition and binding of 
the luciferin substrate by the enzyme for the light producing 
reaction. lueiferase. Therefore. the preferred luciferin ana 
logs for use in preparing tethered compounds are of the 
following formula: 
R2 
N N 00211 
H I 
no X x R3 
The tether or chemical linker is located at either R1. R2. R3 
or R4. X and X‘ may be one of the following: S. 0. EH. 
CH=CH or NR4. When R1 is the site of the tether. R1 is 
—CO2(CH2),,Y. wherein n is 2—15;Y is OH. SH or NH2; and 
R2-R4 are H. When R2 is the site of the tether. R2 can be one 
of the following: —(CH2),,CO2H and ——S(CH2),,Y. wherein 
n is 1-15; Y is OH. SH or NR2; and R1 and R3-R4 are H. 
When R3 is the site of the tether. R3 can be one of the 
following: —CO2H and —(CH2),,Y. wherein n is 1-15; Y is 
OH. SH or NH;', and R,—R2 and R4 are H. When R4 is the 
site of the tether. R4 is —(CH,),,Y. wherein n is 2-15; Y is 
OH. SH or NH2; and Rl-R3 are H. The formula above 
displays luciferin when R1—R3 are H and both X and X‘ are 
both S. 
Luciferin analogs may be synthesized in a number of 
ways. depending on which analog is to be used. 
First. a benzothiazole intermediate is employed in the 
formation of a luciferin analog of the above-formula. The 
5,786,198 
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benzothiazole employed has the following formula: 
HO 
MeO; N 
s _/< 
c0713: 
. 10 
The benzothiazole is synthesized by adding hydrogen sul?de 
to an electron de?cient imino quinone of the following 
formula: 
15 
o 
NJk?/Olit MeOz 
0 
20 
The resulting adduct undergoes dehydration to form the 
luciferin analog. 
A second intermediate. a benzothiazole hydroxy nitrile 
has the following formula: 25 
N 
/>—CN X and X‘ may be one of the following: S. 0. HR. CH=CH 
R0 5 or NR4. The tether or chemical linker of the tethered 
3O molecule occurs in one of four locations on the luciferin 
R is Me. H or PhCH2. The benzothiazole hydroxy nitrile is analog: RP R2. R3. or R4. When the tether is located at R,. 
form?d by adding cyanid? ion to a chlofoalkoxybenlothia- the tethered compound has the following formula: 
zole followed by dealkylation to form the benzothiazole 
nitrile. 35 
Luciferin analogs are then synthesized by adding cysteine 
or a substituted cysteine to either one of the intermediates 
synthesized above. 
N N 
H’ 
no X x 
Once the luciferin analogs are synthesized. these com- 55 R1 is —CO2(CH,),,Z. wherein n is 2 to 15; and Rz-R4 are 
pounds are then reacted in a condensation reaction with the H; Z is O. S 01' NH; A iS 0 01' HH; and G is CH3. C02H. 
activated hypericin to form the tethered molecule of the cozMc- 01' C1123‘ 
fouowing formula: If R2 is the site of the tether. then the compound has the 
following formula: 
5,786,198 
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15 
R2 may be one of the following: -——(CH2),,COZ and 
—S(CH2),,+1Z. wherein n is 1-15; R1. R3 and R4 are H; 2 
is O. NH or S;Ais O or H.H; and Gis CH3. CO2H_ COzMe. 
CH2Br. 
12 
at either of its two carbonyls. The luciferin-porphyrin teth 
ered compounds will be similar in structure to luciferin 
hypen'cin tethered compounds except for the substitution of 
porphyrin for hypericin. i.e.. the luciferin and tether or linker 
When R3 is the site for the tether. the compound has the 20 portion remain the same as those described above. 
following formula: 
N N 
H 
no x x 
R3 may be one of the following: -——COZ and —(CH2),,Z. 
wherein n is 1-15; Rl-R2 and R4 are H; Z is O. NH. or S; 
A is 0 or H11‘, and G is CH3. CO2H. COzMe. CHQBr. 
When R4 is the site of the tether. the compound has the 
following formula: 
m 2H1? \___/ 
C0214 
R4 is —(CH2),,Z. wherein n is 2-15‘, Rl—R3 are H; Z is O. 
NH. or S; A is O. or H,H; and G is CH3. COzH. CO2Me. 
CH2Br. 
The tethered compound may also contain the luciferin 
analogs discussed above linked to the porphyrin compound 
discussed above. As in the luciferin-hypen'cin tethered 
compound. the site of the tether or chemical linker may be 
at R1. R2. R3 or R4. The tether is attached to the porphyrin 65 
When the tethered compound contains a porphyrin instead 
of hypericin the compound has the following general for 
40 mula: 
R2 
N N (10111 
H I 
HO X X R1 
R1 
5.786.198 
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-continued -continued 
OH R = CHZOH 
CH;CH2OH 
C02; 
The tether is attached via R1. R2. R3 or x (through NR4) as Whm Rs is H or CH3 
explained and defined above. Zl-Z6 are each alkyl or 
alkenyl groups containing 1-15 carbon atoms. 
One advantage of combining organic synthesis with virol 
ogy and molecular biology is that organic compounds can be 
designed to exhibit enhanced physical properties. such as 
membrane permeability or polarity. As a consequence. deliv 
ery of these compounds can be targeted to subcellular 25 
organelles or to the cytoplasm. The tethered compounds of 
the invention are also synthesized by direct. high-yield 
synthetic routes. These synthetic routes are ?exible. permit 
ting the facile generation of various related compounds. 
Such compounds may be tested initially for photochemical 
2o 
Particularly preferred tethered compounds are as follows: 
II 
N N C 
H I 
X1 X2 Rt 
H R, n 
45 
properties. and promising molecules may then be further wherein R1 is H. an alkyl or aryl; R2 and R3 are H. OH. Cl. 
characterized biologically. Accordingly. this invention CN or an alkyl; R. is H. OH. an alkyl or aryl. R5 is H or CH3 
encompasses a broad range of tethered compounds that may and R6 is H. OH. C1 or an alkyl; X1 is O. N-alkyl. N-aryl or 
be synthesized and tested by known techniques given the S and X2 is 0- N-alkyl or S; and I1 is 1 I0 10; and m is 1 I0 
teachings of the present invention. 50 4' Most Pmf¢mbly~ RrRe “1'6 H and X1 and X2 are S‘ 
Particularly preferred tethered compounds are composed I11 additic'll- two general types of tethered Compounds may 
of luciferin or a luciferin analog and pseudohypericin (1) or be prepared‘ One type ms a “cage?” lucifm'in wherein the 
its octahydroxy analog (2). shown below, carboxylic acid group present in luciferin is capped as an 
55 activated ester. This ester form of luciferin will not react 
0H 0 OH 1 with luciferase until it is cleaved by esterases within the cell. 
This type of tethered compound exhibits enhanced mem 
brane permeability and is cleaved rapidly by esterases 
present in cells. Preferred tethered molecules of this type are 
Me OR; 60 shown below (3a—3c). Compound 3c contains four mol 
ecules of luciferin per molecule of the hypericin analog. This 
H0 0R5 is signi?cant since once the luciferin interacts with 
luciferase. it is transformed into a different compound which 
can no longer function as a substrate for luciferase. The 
65 hypericin analog. on the other hand. is a catalyst in this 
011 0 0}; reaction. Alternatively. a compound can be prepared as 
shown above wherein up to 10 or more luciferin molecules 
5,786,198 
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are linked together at the COQH and OH ends to form a 
luciferin chain. In such a chain. n is preferably from 1 to 10. 
3a OH O 
OH 
O 
OH 
R/"\ 0 s ' I 
OH O OH 
OH O OH 3b 
M6 I I I OH 
0 O 
/u- 0\/L OH 
R O OH O OH 
36 
N N COZH 
H I .m... 
s 
s 
Tethered compound 3a may be prepared from commer 
cially available (e.g.. CalBiochern) pseudohypericin (1) and 
luciferin using isobutyl chloroformate as a catalyst. Tethered 
compound 3b is made using pseudohypericin. bromoacetic 
anhydride and luciferin. by ?rst reacting pseudohypen'cin 
with bromoacetic anhydride to generate a bromo ester which 
will readily react with the triethylarnrnonium salt of luciferin 
to form 3b. Tethered compound 3c is prepared from quinone 
2 (R=CH2OH) and four molecules of luciferin. Quinone 2 is 
prepared in three steps from 2.6-dichlorobenzoquinone and 
2-methyl ethyl acetoacetate. A water-soluble carbodiirnide 
reagent mediates the reaction between quinone 2 and 
luciferin. A related compound with two methylene groups 
between the aromatic ring and the luciferin subunit can also 
be readily prepared. 
A second type of particularly preferred tethered com 
pound may be generated by combining a “non-caged" 
analog of luciferin with 1 or 2. These tethered compounds 
are not cleaved by esterases. and remain chemically linked 
when added to cells. This enables very e?icient intramo 
lecular energy transfer between hypericin and the chemilu 
minescent intermediate of the reaction of luciferin with 
luciferase. 
We have also developed a particularly preferred enan 
tiospeci?c synthesis of luciferin. The major advantage of our 
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synthesis is the convenient synthesis of luciferin in multi 
gram quantities from inexpensive (less than $l/gram) pre 
cursors. Additionally. this route allows direct access to 
amino analogs of luciferin. This is signi?cant. since various 
amino analogs of luciferin. for example the analog depicted 
below. react with luciferase. 
N N C013 
\ / 21 T 
The preferred route for synthesis of the preferred luciferin 
analogs (4a-4d) is shown below. Compounds 4a and 4b are 
prepared from an intermediate. the benzothiazolehydroxy 
nitrile second intermediate shown above. in the synthesis of 
luciferin. Formation of the allyl ether. Claisen rearrange 
ment and hydroboration are standard organic reactions. The 
reaction of the nilrile moiety with cysteine has precedent 
from the White et al.. J. Am. Chem. Soc, 83. 2402 (1961). 
synthesis and from our synthesis of luciferin. 
H 
1. CH2=CHCHZBL NaH N 
\>_ 2.13 rao-aooo c. CN ‘A3.11101 
HO S 4. cysteine 
N N coat 
‘>—<’ T 
H s 5 
4a 
HO + 
H0 N N cont \>—<’ T 
H s 5 
Luciferin analog 4c is prepared in three steps ?'om an early 
intermediate in the synthesis of luciferin as shown below. 
The chloride is converted into a nitn'le and a cystein unit is 
introduced. Alkylation of an amine with bromoethanol is a 
standard reaction. 
1. KCN, DMSO N 
\ 2.c steine yer-W 2 H 
S 
N N COIH 
\ / 
.HS 1' 
Hz 
OH 
Luciferin analog 4d is prepared as shown below. Nucleo 
philic addition to isothiocyanates (R-NCS) followed by 
alkylation of the resulting intermediate on sulfur with an 
electrophile is a well-established reaction sequence. 
NCS 1. KCN 
2. BrCHgCHgOH 
13. cysteine ; 
TMSO 
5,786,198 
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-continued 
N N C021’! \>—</ 1’ 5 
Ho 5 s 
\/ OH 
Connection of the luciferin analogs with pseudohypericin. 10 
quinone 1. results in the series of particularly preferred 
“non-caged" tethered compounds. Sa-Sd. shown below. 
5,786,198 
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There are a number of analogs of luciferin that react with 
luciferase. including the amino analog and other analogs 
mentioned above. The analogs shown below are also sub 
strates for luciferase. The structural requirements for etfec 
tive substrates are relatively broad. and other analogs may be 
prepared by lmown techniques given the teachings herein. 
OMe 
The tethered compounds of the present invention can 
contain any combination of photosensitizing chemicals and 
energy donating chemicals linked by a tether. providing that 
the energy donating molecule activates the photosensitizing 
molecule in su?icient degree to obtain antiviral or antitumor 
activity. Tether selection is based on (1) the rate of transfer 
from the donor to acceptor and (2) the recognition of the 
substrate by the catalyst for the light producing reaction. The 
rate and quantum yield of the enzyme catalyzed reaction 
may be monitored in order to screen for the potential e?ects 
of inhibition of reactivity. 
A preferred example of a non-luciferin energy donating 
chemical is 1.2-dioxetane. Dioxetane can also readily be 
used to form a tethered compound. as described in more 
detail below and in the examples which follow. The resulting 
stable dioxetane molecule contains both the light acceptor 
and the trigger to create the light. One advantage of this 
system is that it does not require oxygen and thus can be 
used in hypoxic cells. Another particularly advantageous 
aspect of the dioxetane system embodiments of the inven 
tion is that. since the dioxetane molecule also includes a 
trigger moiety (component three) the dioxetane includes all 
three components of the invention. and thus. it can be used 
to inactivate a virus or kill a neoplastic cell by administering 
to the patient a single capsule. injection. or other form of 
administration. 
Any compound bearing a four-membered ring containing 
two oxygen atoms is a “dioxetane.” The structure shown 
below is a 1.2-dioxetane. 
[Z 
l. 2-dioxemne 
HO 
HO 
Because of the ring strain of the foln-membered ring and the 
weak oxygen-oxygen bond. the dioxetane is a labile mol 
ecule. For that reason. most stable dioxetanes have bulky 
substituents which hinder attack by nucleophiles. Dioxet 
anes can be opened either by nucleophilic attack or by 
electron transfer. Steric hindrance from bulky substituents 
does not signi?cantly affect electron transfer. 
Below is illustrated a preferred stable dioxetane A. R is an 
alkyl group which contains the moiety. i.e.. photosensitizing 
chemical. which will accept the light produced and thus 
inactivate the virus or neoplastic cell when the dioxetane 
breaks. The dioxetanes according to the invention may 
contain any of the aforementioned preferred photosensitiz 
ing chemicals or other photoactive chemicals useful for 
PDT. The presently preferred photosensitizing moieties for 
the dioxetane are the hypericins and protoporphyrins. with 
the halide analog of hypericin being most preferred. 
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0-0 
2 l I OR e 
O—G 
stable 
dioxetane A 
O — O 
2 l I OR 
0. 
unstable 
0 
RO —-lL ; 
O_ 
phenoxide B 
excited singlet 
t 
light 
In cases where the above-illustrated R does not contain the 
light-accepting moiety. then this is a short chain alkyl group 
(C1-C7). for example. as shown below. The group G is the 
“trigger” which reacts with a reagent. preferably an enzyme. 
to generate the unstable phenoxide B. For example. if G is 
a carbohydrate such as galactose. then the enzyme beta 
galactosidase can be used to cleave the O—G bond. If G is 
a phosphoric acid derivative or an attendant ester. then a 
suitable reagent would be an alkaline phosphatase. Most 
preferably. G is a polypeptide chain corresponding to a 
sequence cleavable by an HIV protease. thus targeting the 
dioxetane-activation of the photosensitizing chemical to 
HIV infected cells. The reagent may also be a strong base. 
a ?uoride ion or any reagent that cleaves the trigger group 
G to activate the dioxetane. Once the phenoxide B is created. 
it undergoes internal electron transfer with the dioxetane to 
produce an excited-state species which cleaves to give an 
excited singlet (shown above) which reacts with the light 
accepting moiety. The light-accepting moiety can also be 
located on G. as shown below. 
O—O 
OCH; 
Viruses generally encode one or more proteases which 
function to cleave viral polyproteins during viral replication. 
The dioxetane tether is suitably targeted to virus-infected 
cells if the trigger G is a small chain of synthetic peptides 
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which comprise the cleavage site for a given viral protease. 
For example. the cleavage site of retroviral proteases are 
variable. but they share common features. including the 
presence of hydrophobic residues on either side of the 
cleavage site. with some preference to Tyr or Phe preceding 
the cut. and Pro following the cut. Speci?c synthetic peptide 
sequences shown to be cleaved by HIV-1 protease are 
presented in Goobar-Larsson et al.. Virology, 206. 387-394 
(1995). which is incorporated by reference herein in its 
entirety. Additional proteases which target viral proteins 
include the Kex2p endoprotease which cleaves the HIV-1 gp 
160 (Moulard et al.. Biochimie, 76(3-4). 251-6 (1994) and 
Moulard et al.. Eur. J. Biochem, 225(2). 565-72 (1994). 
which are incorporated by reference herein in their entirety). 
The dioxetane tether may also be cleaved by proteases 
expressed at high levels in tumor cells. Membrane-bound 
and secreted proteases are found in many transformed cells 
where they are thought to play a role in mitogenesis and 
metastasis. These include ?bronectin-degrading proteases 
(Chen and Chen. Cell, 48. 193-203 (1987). which is incor 
porated by reference herein in its entirety) and plasminogen 
activators. serine proteases. and collagenases (Dano et al.. 
“Plasminogen Activators. Tissue Degredation. and Cancer." 
Advances in Cancer Res., Vol. 44. 139-164 (1985). which is 
incorporated by reference herein in its entirety). 
When used for treating virus infections such as DNA or 
RNA enveloped virus infections. the ?rst and second com 
ponents of the antiviral composition. preferably in the form 
of a tethered compound. may be administered orally. 
parenterally. and preferably intravenously. In any event. a 
pharmaceutically effective amount of the compound is 
administered. An effective amount is determinable by per 
sons skilled in the art in the view of teachings disclosed 
herein. 
Further. the ?rst and second components. preferably in the 
form of a tethered compound. can be used at dosages 
containing from about 0.001 micrograms to about 100.000 
micrograms per kilogram body weight per treatment. pref— 
erably between about 1 microgram and about 5x104 micro 
grams per kilogram of body weight per treatment 
The duration and number of doses or treatments required 
to control a particular virus will vary from subject to subject. 
depending upon the severity and stage of the illness and the 
subject’s general condition and will also depend on the 
activating chemical. as well as the toxicity (if any) of the 
tethered compound. This will be determinable by persons 
sln'lled in the art in view of the teachings contained herein. 
The total dose required for each treatment may be admin 
istered in divided doses or in a single dose. The preferred 
form of the ?rst and second components. i.e.. the tethered 
compound. may be administered daily. more than once daily. 
one or two times a week. or as determined by the subject’s 
condition and the stage of the disease. 
Those skilled in the art will appreciate that the frequency 
of treatment is subject to optimization. which can be deter 
mined by routine experimentation according to methods 
well known in the art. e.g.. by establishing a matrix of 
dosage and frequency and assigning a group of experimental 
subjects to each point of the matrix. Design of this experi 
ment will preferably take into account the tissue accumula 
tion properties of the compounds of the present invention. 
The present invention also provides pharmaceutical com 
positions and formulations for treating lentiviral infections. 
The ?rst and second components. preferably in the form of 
a tethered compound. can be incorporated in conventional. 
solid and liquid pharmaceutical formulations (e.g. tablets. 
capsules. caplets. injectable and orally administrable 
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solutions) for use in treating mammals that are a?iicted with 
viral infections. The pharmaceutical formulations of the 
invention comprise an effective amount of the tethered 
compounds of the present invention as the active ingredi 
ents. For example. a parenteral therapeutic composition may 
comprise a sterile isotonic saline solution containing 
between about 0.001 micrograms and about 100.000 micro 
grams of the tethered compounds of the present invention as 
described above. It will be appreciated that the unit content 
of active ingredients contained in an individual dose of each 
dosage form need not in itself constitute an e?’ective amount 
since the necessary effective amount can be reached by 
administration of a plurality of capsules. tablets. injections 
or combinations thereof. 
Each formulation according to the present invention may 
additionally comprise inert constituents. including 
pharmaceutically-acceptable carriers. diluents. ?llers. salts. 
and other materials well-known in the art. Selection will 
depend upon the dosage form utilized and the particular 
purpose to be achieved according to the determination of the 
ordinarily skilled artisan in the ?eld. For example. tablets 
may be formulated in accordance with conventional proce 
dures employing solid carriers well known in the art. 
Examples of solid carriers include. starch. sugar. bentonite. 
silica and other commonly used carriers. Propylene glycol. 
benzyl alcohol. isopropanol. ethanol. dimethylsulfoxide 
(DMSO) dimethylacetarnide or other biologically accept 
able organic solvents or aqueous solutions (e.g. water with 
a pH higher than 7 and preferably about 8) may be used as 
diluents. carriers or solvents in the preparation of solid and 
liquid pharmaceutical formulations containing the anti 
lentiviral compositions of the present invention. Further 
nonlirniting examples of carriers and diluents include 
carbohydrates. albumin and/or other plasma protein compo 
nents such as low density lipoproteins. high density lipo 
proteins and the lipids with which these serum proteins are 
associated Such lipids include phosphatidyl choline. phos 
phatidyl serine. phosphatidyl ethanolamine and neutral lip 
ids such as triglycerides. Additional lipid carriers include 
without limitation tocopherol. retinoic acid and cyclodex 
tranes. Semisolid formulations such as those well-known in 
the art (e.g. suppositories) are also contemplated 
Preferred parenteral dosage forms may comprise. for 
example. an isotonic saline solution. containing between 
about 0.1 micrograms to about 100.000 micrograms of the 
tethered compounds of the present invention. 
Capsules employed in the present invention may be made 
from any pharmaceutically acceptable material. such as 
gelatin or cellulose derivatives. Sustained release oral and 
transderrnal delivery systems are also contemplated. as is 
interveneous injection. 
The antiviral and antitumor compositions containing the 
preferred luciferin-hypericin tethered molecule require 
luciferase for the catalysis of the light producing reaction 
and the activation of hypericin. The activation of the light 
source is regulated such that the hypericin is photoactivated 
where needed The regulation of luciferin activation is 
achieved by regulating the expression of luciferase. The 
antiviral or antitumor compositions containing the preferred 
dioxetane compound require a reagent to trigger the diox 
etane. The trigger preferably is a polypeptide that is cleaved 
by a viral or neoplastic protease inside the virus infected or 
tumor cell. thus targeting production of the excited singlet 
and activation of the hypericin or other photosensitizing 
chemical to the infected or tumor cells. 
The third component of the antiviral composition. i.e.. the 
component containing the chemical means for activating the 
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transfer of energy. preferably regulates the expression of the 
activating chemical. In a preferred antiviral composition. the 
activating chemical is luciferase. which is regulated by 
placing the gene encoding luciferase under control of a 
promoter that is transactivated by replication of the virus. By 
placing the expression of luciferase undm control of such a 
promoter. replication of the virus transactivates the viral 
promoter resulting in an increased expression of luciferase 
leading to activation of luciferin and the photoactivation of 
hypericin. ‘These events are localized in virus-infected cells 
thereby targeting the antiviral activity of hypericin. 
Speci?cally. the expression of luciferase is targeted to the 
virus-infected cells by constructing an expression plasmid 
which contains the gene coding for luciferase under control 
of a promoter that is transactivated by repliction of said 
virus. Examples of such promoters include HIV TAR. the 
sequence of which is incorporated herein by reference and 
which is described in Berkhout et al.. Cell 59: 273-282 
(1989); Berkhout et al.. Cell, 62: 757-767 (1990) and 
Berkhout et al.. J. ViroL, 66: 139-149 (1992). all of which 
are incorporated herein by reference. or the consensus 
enhancer sequence present in the promoter of Herpes Sim 
plex Virus alpha genes. the sequence of which is incorpo 
rated herein by reference. and which is described in Fields 
et al.. Virology, Second Ed. 1990. and Mackem et al. J. Virol, 
44: 939-949 (1982) each of which is incorporated herein by 
reference. and the EIAV long terminal repeat GJTR). the 
sequence of which is incorporated herein by reference. and 
which is shown in FIG. 1 of Carpenter et al.. J. ViroL, 65(3). 
1605-1610 (1991). which is incorporated herein by refer 
ence. 
FIG. 3A shows a representation of the expression plasmid 
containing the luciferase gene under control of the EIAV 
MA-l LTR. The plasmid containing the EIAV LTR is 
transfected into CfZth cells and there expresses luciferase in 
the presence of either EIAV or the viral transactivating 
protein. Tat. but not in normal Cf2th cells. In one 
embodiment. the plasmid is ?rst placed into a liposome 
before it is directly transfected into cells. Similar constructs 
containing. for example (FIG. 3B). HIV LTR in place of 
EIAV LTR express luciferase in the presence of HIV or HIV 
Tat. Such HIV constructs can use various different promotor 
sequences. provided that at least one or more Tat-responsive 
cis-acting sequences are included within each promotor 
sequence controlling luciferase expression. See. e.g.. Buch 
schacher et al.. "Human Immunode?ciency Virus Vectors 
for Inducible Expression of Foreign Genes.” J. Virol.. 66:5 
pp. 2731-2739 (1992) and Buchschacher. “Molecular Tar 
gets of Gene Transfer Therapy for HIV Infection." JAMA. 
269:22. pp. 2880-2886 (1993). each of which is incorpo 
rated by reference herein in its entirety. 
Any method of introducing DNA into a cell is su?icient 
for the gene transfer and therapy herein described. Methods 
for transferring DNA into cells include. but are not limited 
to. the use of viral vectors. microinjection. liposome 
mediated. calcium phosphate precipitation and simple naked 
DNA transfer. See Lim et al.. Molec. and Cel. Bio., 7(10): 
3459-3465 (1987); Kasid et al.. PNAS, 87: 473-477 (1990); 
Gilboa. Eli. Retrovirus and Disease, Academic Press. Inc. 
pp. 95-111 (1989); Kantoif et: al. PNAS 83: 6563-6567 
(1986); Kasid et al.. PNAS, 87: 473-477 (1990); Kanto?‘ et 
al.. J. Exp. Med, 166: 219-234 (1987); Cornetta et al.. J. 
Wrol. Math, 23: 187-194 (1989); and Culver et al.. PNAS, 
88: 3155-3159 (1991). The disclosure of each of these 
articles is incorporated herein by reference. 
The third component of the antiviral composition. i.e.. the 
component containing the means for activating the transfer 
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of energy. is preferably introduced into patients through 
gene therapy techniques. In one embodiment. the therapy 
involves retroviral mediated gene therapy that includes 
construction of a retroviral vector in which the DNA encod 
ing the activating chemical. e.g.. luciferase. is placed under 
the control of a modi?ed retroviral promoter which is 
activated in virus-infected cells. In one embodiment. the 
therapy involves ?rst constructing a plasmid vector contain 
ing a retroviral LTR. retroviral packaging sequences. and the 
DNA encoding luciferase. Additionally. the vector may 
contain DNA encoding a selectable marker. e.g.. neomycin 
resistance. 
The plasmid is introduced into a eukaryotic cell or cell 
line. preferably a packaging cell. which harbors stably 
integrated proviral sequences su?icient for expression of 
retroviral structural proteins. but which are de?cient in 
sequences required for packaging and replication of RNA 
transcribed by proviral DNA. Following introduction of the 
plasmid vector. cells containing stably integrated plasmid 
DNA are identi?ed by expression of the selectable marker. 
Encapsidation of vector sequences by the proviral structural 
proteins results in production of retrovirus particles which 
contain genetic material encoding the activating chemical 
under the control of a regulated promoter. Transfected cells 
which produce such retrovirus particles are referred to as 
producer cells. and the virus particle produced from these 
cells is referred to as the retrovirus vector. 
The vector may be introduced into human and mm 
]ian cells in a variety of methods. One method comprises 
removing cells. e.g.. lymph cells from the patients infected 
with the virus to be inactivated. The removed cells are then 
infected with the constructed viral vectors or by other means 
of introducing DNA such as liposome mediated transfer. If 
the DNA is introduced by liposome mediated transfer. the 
liposome contains plasmid DNA containing the promoter 
controlling expression of the activating chemical. the acti 
vating chemical and in some embodiments. a selectable 
marker. The patient cells containing the gene encoding the 
activating chemical are selected through the use of the 
selectable marker. i.e.. cells are selected if they demonstrate 
neomycin resistance. The selected cells are then grown and 
reintroduced into the patient. 
Alternatively. the producer cell lines. constructed as 
described above. are introduced directly into the pan‘ent. 
resulting in infection in vivo. Further. it is possible to 
introduce the vectors directly into the patient. 
In each of the above-described embodiments. the DNA 
encoding the activating chemical is preferably stably inte 
grated within the patient’s cell. Expression of the activating 
chemical is regulated. such that only virus-infected cells 
express high levels of the activating chemical. The fre 
quency of administering the third component via gene 
therapy or other known techniques will depend on how long 
the inserted DNA can be expressed and how long the cells 
containing the inserted DNA will survive. 
In one speci?c embodiment of the invention. the tethered 
compound is used to inactivate HIV. an RNA lentivirus. The 
tethered compound comprises hypericin and a luciferin 
analog. the ?rst and second components. and is administered 
as discussed herein. The third component is administered by 
constructing a viral vector containing (1) a promoter that 
contains HIV TAR and upsteam NF-kB and SP-l sites. or 
sequences necessary for TAT-mediated transactivation. (2) 
the packaging sequences. (3) the luciferase gene and (4) 
Neo'. a neomycin resistance marker. The packaging cell line 
includes a provirus expressing HIV env/gp 120 to target 
CD4 positive cells in which HIV replicates. and no pack 








